Reprogram Biosciences

Reprogram Biosciences is a private, preclinical oncology biotechnology company developing mRNA-based therapeutics for solid tumors. Its core approach is in situ cell reprogramming, using mRNA-encoded gene combinations delivered directly into tumors to induce antigen-presenting function in tumor cells and convert the tumor microenvironment into a site of immune activation. The company positions this as a new immunotherapy class intended to generate systemic antitumor immune responses without relying on exogenous immune-cell therapies. Reprogram also operates an AI-enabled discovery platform, CellRecodeX, which integrates biological foundation models to identify and prioritize reprogramming candidates and expand the pipeline across indications. As of May 2026, the company had raised a total of $6 million in seed financing and remained focused on advancing its lead preclinical program and CMC work.